Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?

出版年份 2020 全文链接

标题

作者

关键词

Biomarkers, Natalizumab, Anti-JCPyV-antibodies, JCPyV DNA-detection, NCCR arrangements

出版物

Multiple Sclerosis and Related Disorders

Volume 41, Issue -, Pages 102008

出版商

Elsevier BV

发表日期

2020-02-13

DOI

10.1016/j.msard.2020.102008

向作者/读者发起求助以获取更多资源

Protocol

在线求助

Reagent

在线求助

Reprint

联系作者

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More